The carboxyl terminus of c-Myb contains a negative regulatory domain that is absent in the v-Myb oncoprotein, but conserved among all the known Myb proteins of animals. This domain inhibits transcriptional activation by c-Myb in animal cells, but not in budding yeast, suggesting that additional protein(s) present in animal cells but not yeast are required for this negative regulatory function. A yeast two-hybrid screen identi®ed BS69, an adenovirus E1A-associated protein, as interacting with the carboxy-terminal region of c-Myb. BS69 contains regions of similarity to the PHD ®nger, the bromodomain, and the MYND domain, all of which are found in other proteins present in high molecular weight complexes that regulate transcription and/or modify chromatin structure. Further study showed that BS69 inhibited the transcriptional activity of c-Myb, that this inhibition was speci®c, that it mapped to the carboxyl termini of the two proteins and that it was dosedependent. A direct interaction between these two proteins was observed in vitro. Furthermore, the 289R E1A protein could inhibit the BS69-mediated decrease in transcriptional activation by c-Myb. By analogy with the inhibition of the Rb/E2F regulatory axis by E1A, we propose that a BS69/Myb regulatory circuit may also be a target of disruption during oncogenesis. Oncogene (2001) 20, 125 ± 132.
Introduction
The Myb gene family was ®rst identi®ed by the presence of the v-Myb oncogene in the avian myeloblastosis virus (AMV), a retrovirus that causes acute monoblastic leukemia in chickens (reviewed in Ganter and Lipsick, 1999) . Like most other retroviral oncogenes, v-Myb arose by viral transduction of a portion of a normal cellular proto-oncogene, in this case c-Myb. AMV encodes an oncogenic v-Myb protein in which signi®cant portions of both the amino and carboxyl termini of c-Myb have been deleted (Figure 1 ). The c-Myb gene has also been activated by retroviral insertional mutagenesis in avian lymphoid and murine myeloid malignancies. Truncation of either the amino or carboxyl terminus of c-Myb occurs in these tumors as well. Recently a similar carboxyterminal truncation of c-Myb has been reported during the progression of a human leukemia (Tomita et al., 1998) . The construction and testing of recombinant retroviruses has demonstrated that such protein truncations greatly enhance the oncogenic potential of the c-Myb protein (Dini and Lipsick, 1993; Grasser et al., 1991) .
The c-Myb gene is required for murine fetal hematopoiesis (Mucenski et al., 1991) . In addition, all vertebrates examined thus far contain two additional closely related genes, A-Myb and B-Myb (Nomura et al., 1988) . The A-Myb gene is required for spermatogenesis and for mammary gland proliferation in the laboratory mouse (Toscani et al., 1997) . In contrast to the tissue-speci®city of expression and action of c-Myb and A-Myb, the B-Myb gene appears to be expressed in all dividing cells of vertebrates (Saville and Watson, 1998) . Consistent with this pattern of expression, BMyb is absolutely required for all but the earliest stages of embryonic development in the laboratory mouse (Tanaka et al., 1999) . Invertebrates such as the sea urchin and the fruit¯y have only one closely related Myb gene (Coman et al., 1997; Katzen et al., 1985) .
The hallmark of the Myb protein family is the presence of a 50 amino acid Myb domain, three of which are present in tandem repeats near the amino terminus of the Myb proteins of animals (Lipsick, 1996) . The second and third repeats are necessary and sucient for sequence-speci®c DNA binding (Biedenkapp et al., 1988; Klempnauer and Sippel, 1987) . Each repeat adopts a structure related to that of the helix ± turn ± helix motif found in repressors of prokaryotes and in the homeodomains of eukaryotes (Ogata et al., 1994) . Deletion of the ®rst repeat of c-Myb causes a decrease in DNA binding and an increase in oncogenic transformation of myelomonocytic cells (Dini and Lipsick, 1993) .
The central region of c-Myb contains a transcriptional activation function that is distributed among several regions of the protein that include an acidic domain and a heptad leucine repeat (Chen et al., 1995; Sakura et al., 1989; Weston and Bishop, 1989) . The central acidic domain appears to be required for the binding of c-Myb to the CBP transcriptional coactivator (Dai et al., 1996; Oelgeschlager et al., 1996) . Both of these transcriptional activation motifs are well conserved in A-Myb, but not in B-Myb or the Myb proteins of invertebrates (Ganter and Lipsick, 1999) .
The carboxyl terminus of c-Myb can function as a negative regulator of both transcriptional activation and of oncogenic transformation Grasser et al., 1991; Sakura et al., 1989) . In contrast to the central region of c-Myb, the carboxyl terminus contains several sequence motifs that are conserved in A-Myb, B-Myb, and the Myb proteins of invertebrates (Ganter and Lipsick, 1999) . A direct physical interaction between the DNA-binding domain and the Cterminus of c-Myb has been observed using yeast twohybrid assays and phage display (Dash et al., 1996; Kiewitz and Wolfes, 1997) . In addition, the carboxyl terminus of c-Myb can inhibit the central transcriptional activation domain in heterologous fusion proteins in which the Myb DNA-binding domain has been replaced by those of GAL4 or LexA (Dubendor et al., 1992; Kalkbrenner et al., 1990) . These results imply a functional interaction between the central activation domain and the carboxyl terminus of c-Myb that does not require the Myb DNA-binding domain.
In budding yeast, no negative regulation by the carboxyl terminus of c-Myb was observed using either intact Myb proteins or GAL4-Myb fusions (Chen and Lipsick, 1993; Seneca et al., 1993) . These results suggest that additional protein(s) present in animal cells but not in yeast are required for the negative regulation of c-Myb by its carboxyl terminus. Using the yeast two-hybrid system we have identi®ed BS69, an adenovirus E1A-binding protein (Hateboer et al., 1995) , as a negative regulator of c-Myb via its interaction with the carboxyl terminus.
Results and discussion
Yeast two-hybrid screen for genes encoding proteins that interact with the carboxyl terminus of c-Myb
We previously reported that full-length c-Myb can activate transcription in budding yeast and that a carboxy-terminal truncation similar to that found in vMyb reduces this activation by about 50% (Chen and Lipsick, 1993) . Others have analysed a series of internal deletions of c-Myb in budding yeast and have concluded that the carboxyl terminus contains a transcriptional activation domain (Seneca et al., 1993) . In order to use the carboxyl terminus of c-Myb as`bait' in a standard yeast two-hybrid screen, it is essential that a GAL4 fusion to this domain not activate transcription on its own (Chien et al., 1991) . We therefore constructed yeast plasmids that encode the GAL4 DNA-binding domain (residues 1 ± 147) fused to the c-Myb central region and carboxyl terminus (GAL4-CC), the c-Myb central region alone (GAL4-Cd), or the c-Myb carboxyl terminus alone (GAL4-dC). GAL4-CC and GAL4-Cd displayed considerable transcriptional activation when tested in an appropriate yeast reporter strain. However, GAL4-dC was inactive. Similar results were obtained with a related series of animal cell expression vectors (Dubendor et al., 1992; DM Wang, unpublished results) . These results demonstrated that the carboxyl terminus of c-Myb does not function as a transcriptional activation domain in the absence of the c-Myb DNA-binding domain, either in budding yeast or in animal cells. Therefore, the GAL4-dC protein that contains the entire carboxyl terminus of c-Myb that is absent in v-Myb was used as`bait' in a yeast twohybrid screen of a mouse embryonic cDNA library fused to the HSV VP16 activation domain (Hollenberg et al., 1995) . This library was designed to produce small functional domains of proteins, rather than full-length proteins that might be subject to intramolecular masking.
We screened 7.7610 6 cotransformants of the mouse embryonic cDNA library fused to the VP16 activation domain and the GAL4-dC expression vector. After rescreening initial positives and ruling out false positive using GAL4-lamin C, we identi®ed six individual positive clones that were analysed futher. Four of these six clones encoded the carboxyl terminus of BS69, a protein previously identi®ed in a bacterial expression library screen using the adenovirus E1A protein as a probe (Hateboer et al., 1995) .
BS69 contains sequence motifs consistent with transcriptional repression
The BS69 protein has been shown to bind directly to the adenovirus E1A protein and to inhibit transcriptional activation by E1A. The region of BS69 that we identi®ed in our two-hybrid screen as the c-Mybbinding domain (CMBD) includes the region of BS69 that is required for binding to E1A (Figure 2) . A more detailed analysis of the sequence of the BS69 protein revealed the presence of three conserved domains that have been identi®ed in other proteins that regulate transcription without binding directly to DNA. Near the amino terminus of BS69 is a cysteine-rich PHD ®nger similar to that found in the Mi-2 protein that is major component of the histone deactylase complex of vertebrates (Wade et al., 1998) . Mutation of a related PHD ®nger in the ATRX protein causes mental retardation and thalassemia in humans (Gibbons et , 1997) . Adjacent to the PHD ®nger is a sequence related to the bromodomain of the SWI2/SNF2/BRM proteins and the CBP/p300 proteins, a motif that can speci®cally bind to acetylated lysine residues (Dhalluin et al., 1999) . Finally, near the carboxyl terminus of BS69 within the CMBD is a MYND domain similar to that found in the ETO/MTG8 protein that is fused to AML1 in acute myelogenous leukemia in humans (Gross and McGinnis, 1996) . Recent studies of the AML1-ETO fusion proteins have shown that the MYND domain can bind N-CoR, thereby recruiting a histone deacetylase complex that causes transcriptional repression (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998) . A similar interaction between N-CoR and BS69 has recently been reported (Masselink and Bernards, 2000) . Intriguingly, a related motif is also found within the CBP/p300 proteins. The presence of a PHD ®nger, a bromodomain, and a MYND domain within BS69 is consistent with the observation that this protein can inhibit transcriptional activation by E1A.
BS69 binds to full-length c-Myb in vitro
The yeast two-hybrid screen described above revealed an interaction between the carboxyl termini of c-Myb and BS69. To test whether the two full-length proteins were also capable of interaction, we used a coupled in vitro transcription/translation system to produce radiolabelled c-Myb proteins and unlabeled BS69 protein that contained the in¯uenza virus HA epitope tag. Full length c-Myb (CCC), an amino terminal truncation (dCC), and a carboxy terminal truncation (CCd) were all tested for their ability to bind to BS69 by co-immunoprecipitation with anti-HA antibody in the presence of BS69-HA (Figure 3) . Only the fulllength c-Myb protein bound signi®cantly to BS69. These results demonstrate that full-length BS69 and cMyb can interact with one another. Furthermore, either amino or carboxy terminal truncation of c-Myb can disrupt this interaction. We presume that carboxy terminal truncation removes a major binding site for BS69 within c-Myb, whereas amino terminal trunca- 
BS69 inhibits transcriptional activation by c-Myb in animal cells but not in budding yeast
To test whether BS69 binding to c-Myb has functional consequences, we cotransfected BS69 and c-Myb into animal cells in the presence of a Myb-responsive reporter gene (Figure 4 ). Increasing doses of BS69 resulted in corresponding decreases in transcriptional activation by full-length c-Myb (CCC) with approximately 80% inhibition at 5 mg of BS69 plasmid per transfection. In contrast, a c-Myb mutant lacking the carboxyl terminus (CCd) did not show signi®cant inhibition. We also found that the CMBD region of BS69 itself was sucient for inhibition of c-Myb (data not shown). These results suggest that the binding of BS69 to the carboxyl terminus of c-Myb that was observed in yeast two-hybrid assays and in coimmunoprecipitation assays results in the inhibition of transcriptional activation by c-Myb in living cells.
Because the carboxyl terminus of c-Myb does not function as a regulatory domain in budding yeast, we wished to test whether the addition of BS69 could restore this negative regulation. We therefore expressed the human BS69 protein in yeast under control of the ADH promoter and tested for inhibition of transcriptional activation either by cMyb proteins or by GAL4-Myb fusion proteins ( Figure 5 
E1A can overcome the inhibition of c-Myb by BS69
The adenovirus E1A protein has been shown to bind to members of the Rb tumor suppressor family, thereby relieving inhibition of genes regulated by the E2F transcription factor (Dyson, 1998) . Because BS69 was ®rst discovered as an E1A-binding protein, we wished to test whether E1A might relieve BS69-mediated inhibition of c-Myb regulated genes in a similar fashion. Transient transfection analysis in animal cells revealed that the addition of the 289 amino acid form of E1A that binds to BS69 caused an increase in transcriptional activation by c-Myb as might be expected if E1A displaced the endogenous BS69 from c-Myb (Figure 6a) . Furthermore, increasing doses of E1A were able to overcome the inhibition of c-Myb caused by exogenously added BS69. This eect was not due to alterations in the levels of c-Myb or BS69 themselves (Figure 6b ). In contrast, the 243 amino acid form of E1A that does not bind to BS69 did not relieve the inhibition of c-Myb by exogenous BS69, despite the higher level of expression of the 243 amino acid protein relative to the 289 amino acid protein. Together these results suggest that endogenous BS69 may normally function to inhibit the activity of c-Myb via its conserved carboxyl terminus and that one function of E1A may be to overcome this inhibition.
Interestingly, the B-Myb gene itself is one of the targets of repression by members of the Rb/E2F family that can be relieved by E1A (Lam and Watson, 1993) . The promoter of the c-Myb gene also contains binding sites for E2F, although the role of this factor in the regulation of c-Myb remains unclear. Together these observations suggest that E1A may act at two sequential steps in the same pathway ± ®rst, by relieving Rb/E2F repression to permit transcription of Myb genes; and second, by relieving BS69-mediated inhibition of the function of the Myb proteins themselves (Figure 6c ). The carboxy-terminal truncation of c-Myb by retroviral transduction or insertional mutagenesis in leukemias and lymphomas could provide another means for disrupting a normal BS69/Myb regulatory circuit.
Materials and methods

Plasmids
A yeast plasmid encoding the transactivation and negative regulatory domains of c-Myb fused to the GAL4p DNAbinding domain (GAL4-CC) was created by cloning the EcoRI ± BamHI fragment of pSG424-c-Myb into pMA424 (Ma and Ptashne, 1987; Dubendor et al., 1992) . A plasmid encoding the negative regulatory domain of c-Myb fused to the GAL4p DNA-binding domain (GAL4-dC) was created by cloning the MscI ± BamHI fragment of pSG424-c-Myb into pMA424 digested with EcoRI ®lled in with Klenow, and then digested with BamHI. A plasmid encoding only the transactivation domain of c-Myb fused to the GAL4p DNAbinding domain (GAL4-Cd) was created by cloning the EcoRI ± BclI fragment of pSG424-c-Myb (DMsc ± Xba) (Dubendor et al., 1992) into the EcoRI and BamHI sites of pMA424. The c-Myb DNA-binding domain yeast expression constructs, YDCCC, YDCCd, YDdCC, YDdCd, and YDdGE (v-Myb) were described previously (Chen and Lipsick, 1993) . A yeast expression vector for human BS69 was created by digesting HA-BS69 with XbaI, ®ll-in with Klenow, followed by digestion with HindIII. The resulting fragment was ligated to the vector YL (Chen et al., 1995) that had been digested with PvuII and HindIII.
Retroviral constructs for expression in animal cells of cMyb and the c-Myb mutant proteins have been described elsewhere (Dini and Lipsick, 1993; Dubendor and Lipsick, 1999; Dubendor et al., 1992; Fu and Lipsick, 1997; Grasser et al., 1991) . An expression vector for HA-tagged BS69 was a gift from ReneÂ Bernards (Netherlands Cancer Institute, Amsterdam, The Netherlands). The 289R and 243R E1A animal cell expression constructs were kindly provided by Pat Hearing (SUNY, Stony Brook, NY, USA). The animal cell Myb-responsive reporter, polyA-EW5(7)Luc, was described previously (Fu and Lipsick, 1996) .
Yeast two-hybrid screen and sequence analysis
The target protein consisted of amino acids 1 ± 147 of the GAL4p DNA-binding domain fused to the C-terminus of chicken c-Myb at amino acid 428 in the vector pGBT9 (Bartel and Fields, 1995) . pMA424 c-Myb (DEco-Msc) was digested with XhoI and BamHI and subcloned into the XhoI and BamHI sites of pGBT9 to produce this protein with an appropriate yeast marker. A mouse embryonic cDNA library fused to the VP16 activation domain was generously provided by Stan Hollenberg (Vollum Institute, University of Oregon Medical Center, Portland, OR, USA). The dual reporter strain, HF7c (Feilotter et al., 1994) , was provided by David Beach (Cold Spring Harbor Laboratory, NY, USA). The library screening protocol was a modi®cation of the method of Vojtek et al., (1993) . Genbank database searches were performed by completing three iterations of the PSI-BLAST algorithm (Altschul et al., 1997) . Sequences were aligned using CLUSTAL_X (Jeanmougin et al., 1998) , and shaded using BOXSHADE 3.21 (Michael Baron and Kay Hofmann, Swiss Institute for Experimental Cancer Research and Swiss Institute for Bioinformatics, Epalinges s/Lausanne, Switzerland).
Animal cell transfections, transactivation assays and immunoblots
Transient transfections into QT6 quail ®broblasts were performed as described (Lane et al., 1990) . The transfections Small arrow represents the activation of transcription. Hatched circles represent DNA-binding transcription factors and shaded boxes represent corepressors included the indicated amounts of Myb, BS69, or E1A expression vector DNA; 1 mg of the luciferase reporter; 0.5 mg of the CMV-b-galactosidase internal control; and sucient carrier yeast tRNA to give a total of 10 mg of nucleic acid per sample per 10 cm dish containing &10 6 QT6 cells. For the BS69 titration experiments, empty expression vector plasmid was added to maintain a constant amount of expression vector DNA in all samples. Two days later cell lysates were processed as previously described (Ganter et al., 1998) . Luciferase activity was normalized to b-galactosidase activity, then relative luciferase units were calculated using the activity of each Myb activator without BS69 as 1. Three replicas of each titration curve were performed and error bars were reported as the standard errors of the means. For immunoblots cell lysates were normalized to equal bgalactosidase activities and subjected to SDS ± PAGE on 10% gels. The resolved proteins were transferred to nitrocellulose (BA-S 83, Schleicher and Schuell, Keene, NH, USA) and probed with a mouse monoclonal anti-Myb antibody (Myb 5E at 1 : 5000 (Sleeman, 1993) ) or the rabbit polyclonal anti-BS69 (BS69 7 ± 12 at 1 : 50 000) (NE Ladendor and JS Lipsick, unpublished).
Yeast transactivation assays and immunoblots
Each GAL4-Myb expression vector was cotransformed into the S. cerevisiae strain, GGY1::171, carrying the GAL1-lacZ reporter (Gill and Ptashne, 1987) , with the expression vector for BS69 or with the empty vector, YL. Unfused Myb expression vectors were similarly cotransformed into an appropriate lacZ reporter strain (Chen and Lipsick, 1993) . Liquid assays for b-galactosidase expression were repeated three times. Cell lysates were normalized to equal OD 600 units and immunoblots for protein expression were performed. Coimmunoprecipitation SP73-I-CCC encoding full-length c-Myb (Fu and Lipsick, 1997) and related plasmids were used for in vitro transcription/translation of Myb proteins. The HA-tagged full-length BS69 expression construct under control of the T7 promoter was provided by ReneÂ Bernards. One mg of template was added to each 50 ml reaction of Promega's TNT Coupled Reticulocyte Lysate kit (Madison, WI, USA). The reactions containing the c-Myb templates were radiolabeled with 35 Smethionine. At the conclusion of each reaction 2-mercaptoethanol was added to a ®nal concentration of 1 mM. For binding reactions 20 ml of each c-Myb protein and 20 ml of BS69 were incubated together at 48C for 45 min. The binding reactions were diluted to 500 ml in E1A lysis buer (50 mM HEPES pH7.0, 250 mM NaCl, 0.1% NP-40, 1 mM 2-mercaptoethanol, 1 mM PMSF), HA antibody (BAbCO, Berkeley, CA, USA) was added, and incubated with rotation at 48C for 45 min. Forty ml of 50% Protein G-sepharose beads in E1A lysis buer plus 5 mg/ml BSA were added and incubated with rotation at 48C for 30 min. The pellet was washed three times in E1A lysis buer and resolved by SDS ± PAGE on a 10% acrylamide gel.
